Amgen Inc. (AMGN)

201.09
NASDAQ
Prev Close 203.97
Day Low/High 200.52 / 206.00
52 Wk Low/High 200.47 / 276.69
Exchange NASDAQ
Shares Outstanding 563.27B
Market Cap 114.89B
P/E Ratio 20.43
Div & Yield N.A. (N.A)

Latest News

'Achieve' High Returns With These 3 Dividend Growth Stocks

'Achieve' High Returns With These 3 Dividend Growth Stocks

These names are among our favorite Dividend Achievers, those companies with at least a decade of dividend growth.

Black Monday Recollections, Bitcoin ETF Launch, Fed Numbers, FDA, Disney's Dip

Black Monday Recollections, Bitcoin ETF Launch, Fed Numbers, FDA, Disney's Dip

While cryptocurrencies are indeed an asset class, and they are divisible, they do not serve as a medium of exchange, and remain unproven as a store of value.

3 Big Pharma Buys for Dividend Investors

3 Big Pharma Buys for Dividend Investors

In a market with elevated valuations and low yields, we see pharmaceutical stocks as a respite from both.

Market on Eggshells, Masking Up, ISM, Pfizer and Moderna Just Getting Started

Market on Eggshells, Masking Up, ISM, Pfizer and Moderna Just Getting Started

Doesn't the Fed now have to taper asset purchases simply to avoid becoming an even greater force in these markets?

How Now, Dow Jones?

The Dow Jones Industrial Average is being dragged down by Amgen , Microsoft and Boeing .  

My Beautiful Balloon, Unmasking the Market, Crypto Risk, Preparing for Powell

My Beautiful Balloon, Unmasking the Market, Crypto Risk, Preparing for Powell

With the economy apparently growing robustly, the Fed has to watch how the president's plans play out in terms of the size and scope of deficit spending.

The Pullback Is on Schedule

The Pullback Is on Schedule

Now, let's look at 2000, and see if we can spot any similarities....

Amgen Looks Ready for an Upside Breakout

Amgen Looks Ready for an Upside Breakout

Traders could go long at current levels risking below $240 for now.

Jim Cramer: Robbing Peter to Pay Paul

Jim Cramer: Robbing Peter to Pay Paul

Let's review this Archegos drama and some lessons from this fickle market.

A Market No-Doubter, Vaccine Milestone, GDP Green Shoots, Inovio, Amazon, Google

A Market No-Doubter, Vaccine Milestone, GDP Green Shoots, Inovio, Amazon, Google

The fact is that even if there is some compromise, the next fiscal stimulus package will be closer to $1.9 trillion than $600 billion.

Jim Cramer: Here's Why the Market Is Cheering Georgia's Results

Jim Cramer: Here's Why the Market Is Cheering Georgia's Results

The fears of what would happen from Democratic wins in Georgia's race failed to pan out, aside from tech taking a few hits. Here's what's happening instead and why.

Real Money Post Industrial Average Bests Most Major Indexes in 2020

Real Money Post Industrial Average Bests Most Major Indexes in 2020

As we enter the new year, there's little time to reflect on RMPIA's strong performance. Now, it's all eyes on the 12 months ahead of us.

My 10 'No Doubt' Predictions for 2021

My 10 'No Doubt' Predictions for 2021

From Amazon to Zoom, here are my prognostications and best ideas for the new year.

Amgen Rated New Buy at Daiwa

Let's See How These Dividend Gifts Stack Up

Let's See How These Dividend Gifts Stack Up

Let's compare several dividend increases in time for the holidays -- and see who wins the 'derby.'

Bearish Bets: 2 Nasdaq Stocks You Should Consider Shorting This Week

Bearish Bets: 2 Nasdaq Stocks You Should Consider Shorting This Week

These names are displaying technical deterioration.

A 3% Dividend Yield With Growth in the Pipeline

A 3% Dividend Yield With Growth in the Pipeline

With four consecutive flat quarterly dividends, this pharmaceutical name could be on the verge of another hefty raise.

Real Money Post Industrial Average Rises 21% Year to Date

Real Money Post Industrial Average Rises 21% Year to Date

The average declined in October, but it was less than that hit took by the major indexes.

Surviving in This Environment, Shaky Recovery, Lilly and Pfizer Setbacks

Surviving in This Environment, Shaky Recovery, Lilly and Pfizer Setbacks

The 'work from home' or 'economic lockdown' trade is close to being back on.

Eli Lilly Could Rally After Passing the Test

Eli Lilly Could Rally After Passing the Test

Successful tests of a rising 200-day moving average line can be great entry points for longs.

No Ordinary Month, Fear September?, Put/Call Ratio, TikTok Bidding War, Amazon

No Ordinary Month, Fear September?, Put/Call Ratio, TikTok Bidding War, Amazon

How September markets digest August ahead of momentous events will be far more important to uptrend maintenance than how August closed.

Pizza, Splits and Stocks

Apple's weight in the (price-weighted) Dow Jones Industrial Average, effective this morning, will be reduced from 12% to 3% -- based on the company's 4-1 stock split. In response to that split, Amgen , Honeywell , and Salesforce are being added to t...

Weakness in September? Dwindling Trading Volume, Fed Speak, Cybersecurity Stocks

Weakness in September? Dwindling Trading Volume, Fed Speak, Cybersecurity Stocks

September, not October, is historically the weakest month of the year for equity markets, though October has had more high profile collapses.

A Healthy Dose of Vaccine and Pharmaceutical Plays

A Healthy Dose of Vaccine and Pharmaceutical Plays

6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.

Amgen Might Be the Right Medicine for the Dow

Amgen Might Be the Right Medicine for the Dow

Let's check the charts as this biotech replaces Pfizer on the DJIA.

Jim Cramer: All These Stocks Are Not Quite 'Dow and Out'

Jim Cramer: All These Stocks Are Not Quite 'Dow and Out'

Let's look at the Dow Jones' swapping of Exxon for Salesforce, Pfizer for Amgen and Raytheon for Honeywell.